<DOC>
	<DOCNO>NCT01606397</DOCNO>
	<brief_summary>The study drug LY2409021 evaluate possible treatment diabetes . The primary purpose study help answer follow research question , provide treatment diabetes : - The safety LY2409021 side effect might associate follow 4 week dose - How long take body absorb remove LY2409021 follow dose 4 week - How daily dose LY2409021 affect blood level sugar ( glucose ) , insulin naturally occur substance meal - How LY2409021 work give metformin - How daily dose LY2409021 affect cell produce insulin</brief_summary>
	<brief_title>A Study Multiple Increasing Doses LY2409021 Participants With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Must either male , female become pregnant , type 2 diabetes either control diabetes diet exercise , take metformin Have hemoglobin A1c ( HbA1c ) value screen great equal 6.5 % less equal 10.0 % stable treatment regimen time measurement Have screen body mass index ( BMI ) 20 40 kg/m^2 inclusive Have blood pressure read screen 90 160 millimeter mercury ( mmHg ) ( systolic ) 40 95 mmHg ( diastolic ) Have use insulin diabetic control within 1 year study entry Have use thiazolidinediones within 3 month , drug treatment hyperglycemia ( except metformin ) within 1 month , prior first plan dosing . Metformin acceptable study . Have clinically significant coronary artery disease Have clinically significant peripheral vascular disease Have clinical evidence active diabetic proliferative retinopathy Have know significant autonomic neuropathy evidence urinary retention , orthostatic hypotension , diabetic diarrhea gastroparesis Impaired renal function ( serum creatinine great 115 micromoles/liter [ μmol/L ] [ 1.3 mg/dL ] woman , great 130 μmol/L [ 1.5 mg/dL ] men ) Have triglyceride great 4.5 millimoles per liter ( mmol/L ) [ approximately 400 mg/dL ] screen Were hospitalize poor control diabetes ( ketoacidotic episode ) last 6 month Are allergic LY2409021 similar drug Have history presence cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine ( diabetes ) , hematological , neurological disorder capable significantly alter absorption , metabolism elimination drug constitute risk take study medication interfere interpretation data Have use systemic glucocorticoid within 1 month prior first dose Have donate 450 mL blood last 3 month donate blood within last month Have regular alcohol intake great 21 units/week ( male ) , 14 units/week ( female ) , unwilling stop alcohol require study restriction ( 1 unit = 360 mL beer , 150 mL wine , 45 mL spirit )</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>